Market Research Logo

Anterior Uveitis - Pipeline Review, H2 2015

Anterior Uveitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Anterior Uveitis - Pipeline Review, H2 2015’, provides an overview of the Anterior Uveitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Anterior Uveitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Anterior Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Anterior Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Anterior Uveitis Overview
Therapeutics Development
Pipeline Products for Anterior Uveitis - Overview
Pipeline Products for Anterior Uveitis - Comparative Analysis
Anterior Uveitis - Therapeutics under Development by Companies
Anterior Uveitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Anterior Uveitis - Products under Development by Companies
Anterior Uveitis - Companies Involved in Therapeutics Development
Aciont Inc.
Aldeyra Therapeutics, Inc.
EyeGate Pharmaceuticals, Inc.
Kineta, Inc.
Neuroptis Biotech
Virogenomics, Inc.
XOMA Corporation
Anterior Uveitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
dalazatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone sodium phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gevokizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LME-636 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOP-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptides to Modulate TCR for Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anterior Uveitis - Recent Pipeline Updates
Anterior Uveitis - Dormant Projects
Anterior Uveitis - Product Development Milestones
Featured News & Press Releases
May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial
Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial
Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases
Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program
Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences
Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis
Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis
Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437
Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anterior Uveitis, H2 2015
Number of Products under Development for Anterior Uveitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Anterior Uveitis - Pipeline by Aciont Inc., H2 2015
Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015
Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015
Anterior Uveitis - Pipeline by Kineta, Inc., H2 2015
Anterior Uveitis - Pipeline by Neuroptis Biotech, H2 2015
Anterior Uveitis - Pipeline by Virogenomics, Inc., H2 2015
Anterior Uveitis - Pipeline by XOMA Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Anterior Uveitis Therapeutics - Recent Pipeline Updates, H2 2015
Anterior Uveitis - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Anterior Uveitis, H2 2015
Number of Products under Development for Anterior Uveitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report